31. 研究成果
實驗室近五年論文發表:
Su-Peng Yeh; Chang-Fang Chiu; Wen-Jyi Lo; Chiao-Ling Lin; Chung-
Tsen Hsueh; Yu-Mine Liao; Ying-Chun Shen; Low Infectious
Morbidity in Patients of Heavily Pretreated Hematological Malignancies
Receiving Autologous Peripheral Blood Stem Cell Transplantation
Without Antimicrobials Prophylaxis; Annals of Hematology, 2003, 82:
p24-29
S-P Yeh, J-G Chang, C-L Lin, W-J Lo, C-C Lee, C-Y Lin, C-F Chiu.
Mesenchymal stem cells can be easily isolated from bone marrow of
patients with hematological malignancies but the surface antigens
expression may be changed after prolonged ex vivo culture. Leukemia,
2005; 19 (8), p1505-1507
S-P Yeh, J-G Chang, W-J Lo, Y-C Liaw, C-L Lin, C-C Lee, C-F Chiu.
Induction of CD45 expression on bone marrow-derived mesenchymal
stem cells. Leukemia, advance online publication 9 March 2006.
L-Y Bai, C-F Chiu, C-W Lin, N-Y Hsu, C-L Lin, W-J Lo and M-C
Kao. Differential expression of Sonic hedgehog and Gli1 in
32. 研究成果
實驗室近五年研討會發表:
Lo WJ, Lin CL, Yeh SP, Chiou CF, Cheng JL, Purification of Mononuclear
Cells From Incompatible Allogeneic Bone Marrow by Using CS-3000 Plus Cell
Seperator. 中華民國醫檢學會九十一年度年會 ; p.37 台北 ; 2002/11/3, (oral
presentation)
Lin CL, Yeh SP, Chiou CF, Lo WJ, Cheng JL, Autologous Peripheral Blood
Stem Cell Transplantation-the China Medical College Hospital Experience. 中
華民國醫檢學會九十一年度年會 ; p.39 台北 ; 2002/11/3, (oral presentation)
羅文吉 葉士 陳鴻震 林嬌玲 廖裕民 邱昌芳 周 基芃 寬 The Best Timing for
PBSC Harvest After the Administration of G-CSF 中華民國血液病學會 / 血液
及骨髓移植學會聯合學術年會 ; p.66 高雄 ; 2003/3/15, (oral presentation)
葉士 吳蜜蘭 廖育晴 羅文吉 林嬌玲 張建國 邱昌芳芃 Isolation and in
vitro expansion of mesenchymal stem cell from bone marrow of patients with
leukemia, myeloma, and aplastic anemia. 中華民國血液病學會 / 血液及骨髓
移植學會聯合學術年會 ; p.13 台北 ; 2004/3/14, (oral presentation)
張韶恩 羅文吉 郭仁懿 陳如娟 施木青 二種不同白血球過濾器過濾效率之評
估 中華民國醫檢學會九十三年度年會 ; PD04 台北 ; 2004/11/3, (Poster
presentation)
33. 實驗室近五年研討會發表:
Su-Peng Yeh, Chang-Fang Chiu, Yu-Min Liao, Wen-Jyi Lo, Yu-Ching Liaw, Chiao-Lin Lin,
Jan-Gowth Chang, Chung-Tsen Hsueh. Serum level of IL-10 correlates well with the activity
of chronic graft-versus-host disease and the responsiveness to corticosteroid treatment. Blood
(ASH Annual Meeting Abstracts), 2004; 104(11); 458a. (Poster presentation at 2004 Annual
meeting of American Society of Hematology; San Diego, Dec. 4-7/2004)
葉士 廖裕民 廖育晴 羅文吉 林嬌玲 張建國 邱昌芳芃 Plasma Level of Interleukin-10
Correlates Well with the Activity of Graft-Versus-Host Disease and the Responsiveness to
Immunosuppressive Treatment 中華民國血液病學會 / 血液及骨髓移植學會聯合學術年會 ;
p.24-26 高雄 ; 2005/3/26, (oral presentation)
葉士 吳蜜蘭 廖育晴 羅文吉 林嬌玲 張建國 邱昌芳芃 Mesenchymal Stem Cells Can
Be Easily Isolated from Bone Marrow of Patients With Various Hematological Malignancies
But The Surface Antigens Expression May Be Different From Patient to Patient and Passage
to Passage 中華民國血液病學會 / 血液及骨髓移植學會聯合學術年會 ; p.66 高雄 ;
2005/3/27, (oral presentation)
Su-Peng Yeh, Chang-Fang Chiu, Yu-Min Liao, Chiao-Lin Lin, Wen-Jyi Lo, Cheng-Chun Lee.
Abnormal bone marrow derived mesenchymal stem cell: another clone in hematological
malignancy? Blood (ASH Annual Meeting Abstracts), 2005; 106(11); 404a. (Poster
presentation at 2005 Annual meeting of American Society of Hematology; Atlanta, Dec. 10-
13/2005)
研究成果
34. 實驗室近五年研討會發表:
葉士 廖裕民 羅文吉 林嬌玲 邱昌芳芃 Abnormal Bone Marrow-Derived Mesenchymal
Stem Cell ( Bone Marrow Stromal Cell): Another Clone in Hematological Malignancy? 中華
民國血液病學會 / 血液及骨髓移植學會聯合學術年會 ; p.23-24 台中 ; 2006/3/18, (oral
presentation)
葉士 廖裕民 廖育晴 羅文吉 林嬌玲 張建國 邱昌芳芃 Post Transplant Immune
Monitoring: New Insight in the Management of Graft-Versus_Host Disease. 中華民國血液
病學會 / 血液及骨髓移植學會聯合學術年會 ; p.23-24 台中 ; 2006/3/19, (oral presentation)
廖裕民 葉士 林振源 黃馨慧 白禮源 羅偉忠 謝清昀 羅文吉 林嬌玲 邱昌芳芃 Autologous
Transplantation Using In Vivo-Purged Peripheral Blood Stem Cells for Relapsed AML:
Clinical Limitation And Future Implication 中華民國血液病學會 / 血液及骨髓移植學會聯
合學術年會 ; p.23-24 台中 ; 2007/03/10, (oral presentation)
羅文吉 葉士 林嬌玲 廖裕民 黃馨慧 林振源 白禮源 羅偉忠 謝清昀 邱昌芳芃 Changing
Characteristics of Bone Marrow-Derived Mesenchymal Stem Cell During Ex Vivo Culture:
Important Consideration For Research And Clinical Application 中華民國血液病學會 / 血液
及骨髓移植學會聯合學術年會 ; 台中 ; 2007/03/10, (oral presentation)
邱昌芳 羅文吉 林嬌玲 廖裕民 林振源 黃馨慧 白禮源 葉士芃 Total Body Irradiation
before Allogeneic Transplantation Results in Chromosomal Abnormalities of Bone Marrow-
Derived Mesenchymal Stem Cells 中華民國血液病學會 / 血液及骨髓移植學會聯合學術年
會 ; 台中 ; 2007/03/10, (oral presentation)
研究成果
35. 研究成果研究成果 (( 一一 ))
Serum IL-10 level correlates well with the activity of GVHDSerum IL-10 level correlates well with the activity of GVHD
Presented at 2004 annual meeting of American Society of Hematology (ASH) & 2006
annual meeting of European Society of Hematology (ESH)
Yeh SP. Blood 2004, 104 (11): 458a
Yeh SP. Hematologica 2006, 91 (S1): 114-115
37. 研究成果研究成果 (( 三三 ))
Gene Expression Profile Between P2 and P5 MSCs
P2 > P5 Patient Normalized expression ratio
Proenkephalin myeloma 0.33
AML 0.38
Normal 0.24
Vimentin myeloma 0.43
AML 0.44
Normal p.40
Chr. 20; open reading frame 129 myeloma 0.26
AML 0.02
Normal 0.26
Cyclin B2 AML 0.15
Normal 0.31
Selenoprotein P myeloma 0.33
P5 > P2
Angiopoietin like-4 AML 13.83
Myeloma 2.62
TGF-alpha AML 27.43
Tissue factor pathway inhibitor AML 8.49
P5 Mesenchymal stem cells (MSCs) is different to P2 MSCsP5 Mesenchymal stem cells (MSCs) is different to P2 MSCs
P2 vimentinP2 vimentin
P5 vimentinP5 vimentin
Submitted to 2006 annual meeting of American Society of Hematology (ASH)
38. 研究成果研究成果 (( 四四 ))
Cytogenetic abnormalties after irradiation
Case No Disease
Chromosome of BM-MSCs
before TBI
Chromosome of BM-MSCs
after TBI
Chromosome of BM-blood cells
after TBI
(Allotransplantation)
1 AML not available
46 XY, t(7;22)(p22;q11),
del (13)(q12q22),
del (15)(a15?)
Normal XX
2 ALL not available
47 XY, del (1)(p36), +2,
t(3;13)(p21;q12),
t(5;10)(q33;p15)
Normal XX
3 ALL Robertsonian variant
46 XY, Robertsonian
translocation,
t(1;17)(q21;p13)
Normal XX
Cytogenetic abnormality of MSCs after irradiationCytogenetic abnormality of MSCs after irradiation
Submitted to 2006
annual meeting of
American Society of
Hematology (ASH)
39. 研究成果研究成果 (( 五五 ))
Gene Expression Profile of MSCs is different betweenGene Expression Profile of MSCs is different between
normal and myelomanormal and myeloma
GEPGEP MM P2> NP2: INF-alpha inducible protein 27; Mannosidase, class IC, memberMM P2> NP2: INF-alpha inducible protein 27; Mannosidase, class IC, member
2 Serine proteinase inhibitor; spondin 2, Tetranectin2 Serine proteinase inhibitor; spondin 2, Tetranectin
NP2 > MMP2: angiotensinogen protinase inhibitor, ectonucleotideNP2 > MMP2: angiotensinogen protinase inhibitor, ectonucleotide
pyrophosphatase keratin associated protein 1-1, podocalyxin-pyrophosphatase keratin associated protein 1-1, podocalyxin-
like, putative NFkB activating proteinlike, putative NFkB activating protein
PathophysiologicalPathophysiological
significance?significance?
40. How MSCs influence the fate of hematological cancer cells?How MSCs influence the fate of hematological cancer cells?
Research grant from NSC 95-2745-B-039-005
Viability 33% Viability 42%
Viability 94% Viability 97%
研究成果研究成果 (( 六六 ))
41. MSCs after TBI showed cytogenetic abnormality with
evidence of clonal evoluation
研究成果研究成果 (( 七七 ))